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Abstract
A great deal of research has pointed to deleterious roles of metal ions in the development of
Alzheimer's disease. These include: i) the precipitation and aggregation of amyloid β (Aβ) peptides
to form senile plaques and neurofibrillary tangles, and/or ii) the augmentation of oxidative stress by
metal ion mediated production and activation of hydrogen peroxide. The growing trend in
nutraceutical intake is in part a result of the belief that they postpone the development of dementias
such as Alzheimer's disease. However, pathogenic events centred on metal ions are expected to
be aggravated by frequent nutraceutical intake. Novel therapeutic approaches centred on chelators
with specificity for copper and iron ions should be fully explored.
Introduction
Dementia currently affects over 750,000 people in the UK,
with Alzheimer's disease (AD) accounting for 55 % of
those cases. As a result of increasing life expectancy, the
number of people predicted to suffer from dementia is
expected to rise to over 1.8 million by 2050. Currently
there are no known cures for AD. Existing treatments at
best only delay the progression of disease and accurate
diagnosis can only be made with certainty at autopsy.
Hence, there is an urgent need for new therapeutic
approaches and for reliable and noninvasive methods to
aid in the early diagnosis of AD and to give an indication
of disease progression. Advanced AD is evident from the
apparent progressive decline in cognitive function as a
result of loss of neurons. These are accompanied by path-
ological changes including extracellular amyloid β
plaques and intracellular changes called neurofibrillary
tangles, which are abnormal deposits of hyperphosphor-
ylated tau proteins [1].
Recent reports ascribe a major role for the metal ions,
iron, copper and zinc in AD. Specifically the redox active
metal ions Fe2+ and Cu+ can generate the highly reactive
and oxidizing species, the hydroxyl radical via the Fenton
reaction. This species is thought to account for a large pro-
portion of oxidative modifications that are seen in AD
brains including lipid peroxidation, nucleic acid oxida-
tion and protein carbonylation. Also metal ions have been
shown to be central to Aβ pathogenicity.
The Aβ peptide is a low molecular weight protein consist-
ing of 39–43 amino acids. It has two high affinity binding
sites, one specific for copper and one specific for zinc. In
the Aβ1–42 peptide (the predominant Aβ species found
in amyloid plaques in AD brains) the high affinity bind-
ing site binds Cu2+ were estimated at log K = 17.2 and 16.3
at pH 7.4 and pH 6.6 respectively, and the low affinity
binding site at log K = 8.3 and 7.5 at pH 7.4 and 6.6
respectively [2]. At physiological pH values, soluble Aβ is
precipitated by Zn2+ in vitro. However, at pH levels reflect-
ing physiological acidosis, which is characteristic of AD, in
vitro precipitation of Aβ is induced by cupric and ferric
ions. Cupric ions induce greater precipitation than ferric
ions, which is thought to be a result of its higher binding
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affinity, with Aβ aggregation enhanced to ~85 % [3]. In
addition, Cu2+ ions are bound at the low affinity site com-
pletely displacing the Zn2+ ions in physiological acidosis
[2]. Levels of copper, iron and zinc have been analyzed in
the rims and cores of senile plaques of AD patients and
concentrations were found to be highly elevated. Concen-
trations exhibited in the senile plaques cores were 22.7 ±
6.5, 52.4 ± 14.5 and 67.0 ± 13.0 µg/g for copper, iron and
zinc respectively [4]. In addition serum copper levels have
been shown to be markedly elevated in AD [5].
The catalytic effects of transition metals on the formation
of reactive oxygen species are becoming evident as a major
factor in AD. Aβ binds to Cu2+ reducing it to Cu+. The Aβ-
Cu+ complex can then trap dioxygen and reduce it to
hydrogen peroxide (H2O2). One study demonstrated that
1 µM Cu2+ when bound to Aβ could catalytically generate
10 µM H2O2, indicating continual redox cycling [6]. In
conditions where this reaction is not favorable, biological
reducing agents such as vitamin C have been shown to
enhance this reaction [7]. The generation of H2O2 has
been shown to be neurotoxic, which is considered to be a
result of its reduction to the hydroxyl radical via Fenton
chemistry. Cupric ion binding is dependent on histidine
and tyrosine amino acid residues. Upon generation of
hydroxyl radicals localized to the Cu2+ ion, the tyrosine
residues can cross-link to form dityrosine. This further sta-
bilizes the Aβ plaques conferring resistance to proteolysis
[8]. Further studies are required to establish if Aβ bound
to Cu2+ and Zn2+ exhibits significant anti-oxidant enzyme
activities (superoxide dismutase and catalase activities) in
vivo, as many researchers have likened Aβ to the native
CuZn superoxide dismutase enzyme in both its conforma-
tion and its metal binding affinities [9].
Magnetite and maghemite deposits have been found in
brains of patients suffering from AD and studies are
underway to correlate enhanced levels with disease pro-
gression [10]. However, magnetite detection is only possi-
ble after the onset of AD. A comprehensive understanding
of the levels and nature of redox-active ferric ions is war-
ranted to assess the mechanisms of magnetite deposition.
AD brains exhibit increased levels of oxidatively modified
nucleic acids, specifically RNA in vulnerable neurons [11].
Haem oxygenase-1 (HO-1), an enzyme which catalyses
the breakdown of haem to biliverdin with release of iron
and carbon monoxide, is over-expressed in the brains of
AD patients. So it could be postulated that this would be
one source of redox-active iron. Immunostaining of neu-
rons demonstrated that HO-1 expression was co-localized
to the neurofibrillary tangles [12]. However oxidative
damage to nucleic acids was reduced in neurons exhibit-
ing neurofibrillary tangles demonstrating an antioxidant
mechanism for HO-1 and an involvement in tau proteins
expression. Further studies on the oxidative modifications
of RNA in AD demonstrated it to be localized to iron rich
lysosomes called lipofuscins originating from the mito-
chondria. This indicates a disruption in mitochondrial
function leading to accumulation of redox-active iron in
the neuronal cytoplasm [13] and subsequent reactive oxy-
gen species generation.
Therapeutic Implications
Oxidative stress is one of the key mechanisms of neuro-
toxicity in AD, and studies have shown that Aβ neurotox-
icity can be partially or completely attenuated by the
antioxidant enzyme catalase [6,7]. Plasma levels of anti-
oxidants including vitamin E, uric acid and vitamin C are
depleted in AD patients [14]. Therefore, many people
have proposed the supplementation of antioxidants such
as vitamin E and vitamin C. Several studies have reported
that increased intake either through diet or supplementa-
tion results in reduced incidence of AD [15-17]. However,
other studies do not report such success [18]. In fact, some
studies have shown that vitamin C which can also act as a
pro-oxidant can also induce neuronal oxidative stress via
its interaction with metal ions [19].
A long-term imbalance in metal ion homeostasis is rarely
treatable by alterations in diet. Therefore, research is
focusing on the development of new methods for thera-
peutic intervention, specifically chelators to remove the
deleterious metal ions, with concomitant dissolution of
the Aβ plaques. In vitro studies on the aggregation of Aβ
induced by metal ions, showed that this was completely
reversible by metal ion chelation [3]. As a result of these
observations new chelators are being developed as novel
therapies for AD, however many are restricted by their
poor target specificity. Clioquinol a Cu/Zn chelator was
tested in APP2576 transgenic mice and appeared to selec-
tively bind the Aβ-metal complex resulting in dissolution
of Aβ plaques, reducing brain Aβ by 49 % [20]. No neuro-
toxicity was exhibited. Clioquinol subsequently was
tested in a clinical trial with 36 AD patients. It affected a
rise in plasma concentrations of zinc, and also decreased
plasma concentrations of Aβ 1–42 [21]. However more
studies are required to determine its importance in treat-
ing AD. Many other metal ion chelators are currently
under investigation for treatment of AD [22-25].
We have developed a series of metal ion chelators for both
the study and treatment of metal deposition disorders.
These include the development of the first-ever, reactive
oxygen and nitrogen species probe for the simultaneous
detection of multiple RONS and the role of redox-active
metal ions in their generation and suppression [26]. Alter-
ation of the basic structure of these probes affords anti-
oxidant enzyme mimics [27]. In addition the chelator
EGTA, which has previously been shown to dissolve Aβ
plaques [28] was also demonstrated to have substantialNutrition Journal 2005, 4:14 http://www.nutritionj.com/content/4/1/14
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superoxide dismutase activity when complexed to redox-
active metal ions [29]. Thus, addition of a chelator that
generates a superoxide dismutase or catalase mimic could
'dissolve' the magnetite deposits and Aβ plaques and
negate oxidative damage arising from them.
Conclusion
Metal specific chelators afford a major opportunity for the
control of metal ion mediated pathogeneses, which is not
currently provided by nutraceuticals. In particular, admin-
istration of "prodrug" chelators that mimic anti-oxidant
enzymes with high specificity for Cu2+ and Fe3+ ions will:
i) counteract oxidative stress, ii) help to control metal ion
deposition and iii) dissolve Aβ plaques and, maghemite
and magnetite residues.
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